What is Molecular Assemblies?
Molecular Assemblies is a private life sciences company dedicated to revolutionizing DNA synthesis. Leveraging a patented enzymatic method that mimics natural DNA production, the company generates long, high-quality, sequence-specific DNA reliably, affordably, and sustainably. This groundbreaking technology is poised to power the next generation of DNA-based products across diverse sectors, including industrial synthetic biology, precision medicine, DNA data storage, nanomachines, and bio-based electronics. Headquartered in San Diego, Molecular Assemblies is at the forefront of enabling advanced DNA reading and writing capabilities.
How much funding has Molecular Assemblies raised?
Molecular Assemblies has raised a total of $57.1M across 6 funding rounds:
Private Equity
$4.5M
Angel/Seed
$2.3M
Debt
$150K
Debt
$325K
Series A
$24M
Series B
$25.8M
Private Equity (2016): $4.5M, investors not publicly disclosed
Angel/Seed (2016): $2.3M led by Agilent Technologies, Newport Holdings, LP, Alexandria Venture Investments, Genomics Investment Syndicate, 11.2 Capital, and Cavendish Impact Capital Fund
Debt (2020): $150K supported by PPP
Debt (2021): $325K featuring PPP
Series A (2021): $24M backed by Argonautic Ventures, Codexis, LYFE Capital, iSelect Fund Management, Alexandria Venture Investments, and Agile Technologies
Series B (2022): $25.8M with participation from LYFE Capital, Argonautic Ventures, Codexis, iSelect Fund Management, Casdin Capital, and Agilent
Key Investors in Molecular Assemblies
LYFE Capital
LYFE Capital is a premier healthcare investment platform that connects healthcare champions with global markets, supply chains, and strategic partners. The company focuses on investing in critical healthcare supply chain assets, specialized product platforms, and next-generation R&D services, aiming to generate significant and resilient revenues from mature global markets.
Argonautic Ventures
Argonautic is a venture capital firm focused on building data-centric companies, particularly in financial technology, construction technology, and computational biotechnology. They invest at the pre-seed to seed stages, providing capital and strategic support to teams aiming to redefine outdated workflows across various industries.
Codexis
Codexis, Inc. is a leading enzyme engineering company headquartered in Redwood City, California, leveraging its proprietary CodeEvolver protein engineering technology platform to discover, develop, and enhance novel, high-performance enzymes and other classes of proteins for use in therapeutics manufacturing, molecular diagnostics, and pharmaceutical applications.
What's next for Molecular Assemblies?
The recent major strategic investment signals a significant scaling phase for Molecular Assemblies. With its enzymatic DNA synthesis technology poised to disrupt multiple industries, the company is likely to focus on expanding its production capabilities, accelerating research and development for new applications, and forging strategic partnerships. This capital infusion will be instrumental in solidifying its market position and driving the adoption of its sustainable and cost-effective DNA synthesis solutions in fields ranging from advanced therapeutics to novel data storage paradigms.
See full Molecular Assemblies company page
